Home » Stocks » ELDN

Eledon Pharmaceuticals, Inc. (ELDN)

Stock Price: $9.49 USD -0.16 (-1.66%)
Updated May 12, 2021 3:59 PM EDT - Market closed
Market Cap 134.48M
Revenue (ttm) n/a
Net Income (ttm) -22.81M
Shares Out 1.45M
EPS (ttm) -15.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $9.49
Previous Close $9.65
Change ($) -0.16
Change (%) -1.66%
Day's Open 9.71
Day's Range 9.26 - 9.71
Day's Volume 11,518
52-Week Range 6.16 - 27.32

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

IRVINE, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons l...

1 week ago - GlobeNewsWire

Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

1 week ago - GlobeNewsWire

As part of ongoing discussions with the FDA regarding Eledon Pharmaceuticals Inc's (NASDAQ: ELDN) AT-1501 renal transplant program, the agency has requested AT-1501 specific renal transplant data in non...

2 weeks ago - Benzinga

IRVINE, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons...

2 weeks ago - GlobeNewsWire

Eledon Pharmaceuticals (ELDN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

2 weeks ago - Zacks Investment Research

David Hovland, Ph.D., to serve as Chief Regulatory Officer and Bryan Smith, J.D. as General Counsel, Corporate Secretary, and Chief Compliance Officer David Hovland, Ph.D., to serve as Chief Regulatory ...

3 weeks ago - GlobeNewsWire

Continued enrollment in Phase 2 clinical trial of AT-1501 in amyotrophic lateral sclerosis (ALS)

1 month ago - GlobeNewsWire

Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

1 month ago - GlobeNewsWire

Eledon to commence trading on the Nasdaq exchange under the ticker “ELDN” effective tomorrow, January 5, 2021

Other stocks mentioned: NVUS
4 months ago - GlobeNewsWire

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics announced the appointment of June Lee, M.D., to the company's Board of Directors.

Other stocks mentioned: NVUS
5 months ago - Business Wire

Novus Therapeutics, Inc. (NVUS) CEO David-Alexandre Gros on Q3 2020 Results - Earnings Call Transcript

Other stocks mentioned: NVUS
5 months ago - Seeking Alpha

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients underg...

Other stocks mentioned: NVUS
5 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients underg...

Other stocks mentioned: NVUS
6 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

Other stocks mentioned: NVUS
6 months ago - Business Wire

Novus Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Other stocks mentioned: NVUS
7 months ago - Zacks Investment Research

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split

Other stocks mentioned: NVUS
7 months ago - Business Wire

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Other stocks mentioned: BBC, BTEC, IBBJ, IDNA, MRNS, NVUS, PTH ...
7 months ago - Zacks Investment Research

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics to Present at H.C.

Other stocks mentioned: NVUS
7 months ago - Business Wire

Novus Therapeutics, Inc. (NVUS) CEO Dr.

Other stocks mentioned: NVUS
7 months ago - Seeking Alpha

IRVINE, Calif. & BOSTON--(BUSINESS WIRE)--Novus Therapeutics Announces Acquisition of Anelixis Therapeutics

Other stocks mentioned: NVUS
7 months ago - Business Wire

Novus Therapeutics (NASDAQ: NVUS) shares are trading lower on Tuesday. Ladenburg Thalmann downgraded the stock from Buy to Neutral and announced a price target of 60 cents per share.

Other stocks mentioned: NVUS
11 months ago - Benzinga

Shares of Novus Therapeutics Inc. NVUS, -49.60% lost nearly half their value in active trading Monday, after the specialty drug maker announced disappointing trial results of its ear infection treatment.

Other stocks mentioned: NVUS
11 months ago - Market Watch

About ELDN

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the trea... [Read more...]

Industry
Biotechnology
Founded
2004
CEO
Gregory Flesher
Employees
10
Stock Exchange
NASDAQ
Ticker Symbol
ELDN
Full Company Profile

Financial Performance

Financial Statements